Managed Access Programs for LNP023, Iptacopan

Conditions

• C3 Glomerulopathy (C3G)
• Paroxysmal Nocturnal Hemoglobinuria (PNH)

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Iptacopan — DRUG
  Patients receive Iptacopan

Study Details

The purpose of this registration form is to list all Managed Access Programs (MAPs) related to LNP023, Iptacopan

Key Dates

Status verified

Dec 2025

Central Contacts

• MAP requests are initiated by a licensed physician.https:// www.novart is.com/healthcare-professionals/managed-access-programs
  1-888-669-6682
  [email protected]
• Novartis Pharmaceuticals
  +41613241111

Related Studies

• Haplo-identical Transplantation for Severe Aplastic Anemia, Hypo-plastic MDS and PNH Using Peripheral Blood Stem Cells and Post-transplant Cyclophosphamide for GVHD Prophylaxis
  PHASE2 · Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Bethesda, Maryland
• A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
  PHASE2 · Recruiting · Apellis Pharmaceuticals, Inc. · Atlanta, Georgia
• Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
  Recruiting · Alexion Pharmaceuticals, Inc. · Boston, Massachusetts
• Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH Patients
  PHASE3 · Recruiting · Novartis Pharmaceuticals · New Brunswick, New Jersey